Antineoplastons: when is enough enough?

Figg, William D

Figg, William D.

Lancet Oncol ; 19(6): 733-734, 2018 Jun.

Article in En | MEDLINE | ID: mdl-29893248

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Glutamine/analogs & derivatives; Neoplasms/drug therapy; Phenylacetates/administration & dosage; Administration, Intravenous; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Evidence-Based Medicine; Glutamine/administration & dosage; Glutamine/adverse effects; Humans; Neurotoxicity Syndromes/etiology; Patient Safety; Phenylacetates/adverse effects; Quackery; Risk Assessment; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylacetates / Antineoplastic Combined Chemotherapy Protocols / Glutamine / Neoplasms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google